Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.91 |
| ▸ | DRD2 | P14416 | 3/20 | 0.91 |
| ▸ | HTR1A | P08908 | 1/20 | 0.91 |
| ▸ | HTR2A | P28223 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6518729 | 0.99 | HTR6 (0.89) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| SCHEMBL4675288 | 0.95 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| SCHEMBL4309774 | 0.86 | HTR6 (0.82) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| SCHEMBL4307633 | 0.85 | HTR6 (0.67) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL6518370 | 0.85 | HTR6 (0.80) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL4309912 | 0.85 | HTR6 (0.80) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| SCHEMBL5698341 | 0.85 | HTR6 (0.80) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL6518321 | 0.84 | HTR6 (0.65) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| SCHEMBL4312562 | 0.82 | HTR6 (0.77) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6514255 | 0.81 | HTR6 (0.76) | HTR6DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | claimed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | HTR6 1/4885DRD2 51/4885HTR1A 2/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | HTR6 1/4885DRD2 50/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.